목적: 근시성 맥락막 신생혈관에서 유리체강내 라니비주맙 주입술의 효과를 평가해보고자 하였다. 대상과 방법: 근시성 맥락막 신생혈관으로 유리체강내 라니비주맙 주입술을 시행한 환자들 중에서 추적관찰 기간이 6개월 이상인 경우 를 대상으로 의무기록을 후향적으로 조사하여 술 전, 술 후 1개월, 3개월, 6개월째에 최대교정시력, 빛간섭단층촬영에서 중심황반두께, 형광안저촬영에서 누출 정도를 비교분석하였다. 결과: 총 18명 21안으로 평균최대교정시력(logMAR)은 술 전 1.23±0.65에서 술 후 1개월째 0.96±0.40, 3개월째 0.95±0.67, 6개월째 0.83±0.58로 유의하게 호전되었으며(p <0.001, p=0.006, p=0.001) 평균 중심황반두께는 술 전 233.42±65.55 μm에서 술 후 3개월째 204.14±65.29 μm, 6개월째 157.76±71.45 μm으로 유의하게 감소되었다(p<0.001). 술 후 6개월째 형광안저촬영에서 12안에서 형광누 출이 없어졌고 9안에서 섬유화 소견을 보였다. 결론: 한국인에서 근시성 맥락막 신생혈관의 유리체강내 라니비주맙 주입술은 시력의 향상 및 병변의 호전을 보여 효과적으로 나타났다.

Purpose: To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV). Methods: Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection. Results: Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23±0.65, 0.96± 0.40, 0.95±0.67, and 0.83±0.58 at baseline, 1, 3, and 6 months, respectively (p<0.001, p=0.006, p=0.001). The mean central macular thickness was 233.42±65.55 μm, 204.14±65.29 μm, and 157.76±71.45 μm at baseline, 3, and 6 months, respectively (p<0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes. Conclusions: Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.

Purpose: To evaluate the effects of intravitreal ranibizumab in myopic choroidal neovascularization (CNV). Methods: Patients who underwent intravitreal ranibizumab injection for myopic CNV, and were followed up more than 6 months, and their records were retrospectively investigated. The best corrected visual acuity, central macular thickness, and leak in fluorescein angiography were compared at baseline, and at 1, 3, and 6 months after injection. Results: Twenty-one eyes of 18 patients were evaluated. The mean best corrected visual acuity (logMAR) was 1.23±0.65, 0.96± 0.40, 0.95±0.67, and 0.83±0.58 at baseline, 1, 3, and 6 months, respectively (p<0.001, p=0.006, p=0.001). The mean central macular thickness was 233.42±65.55 μm, 204.14±65.29 μm, and 157.76±71.45 μm at baseline, 3, and 6 months, respectively (p<0.001). In fluorescein angiography at 6 months after injection, regression was observed in 12 eyes, and fibrosis in 9 eyes. Conclusions: Intravitreal ranibizumab injection for myopic CNV in Korean patients appeared to be effective, resulting in regression of lesion and improvement of visual acuity.